The least squares (LS) mean changes in serum sclerostin were − 9.15%, + 1.87%, + 3.54%, and + 1.06% among acute ADT users, chronic ADT users, former ADT users, and PCa controls, respectively (Fig. 1a). This evidence concerns the gene SOST and posterior cortical atrophy.